Ensign Peak Advisors
AKRO

Ensign Peak Advisors’s Akero Therapeutics AKRO Stock Holding History

Ensign Peak Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-207,692
Closed -$9.86M – 1685
2025
Q3 		$9.86M Buy
207,692
+19,283
+10% +$934K 0.02% 460
2025
Q2 		$10.1M Buy
188,409
+33,365
+22% +$1.52M 0.02% 470
2025
Q1 		$6.28M Hold
155,044
– – 0.01% 579
2024
Q4 		$4.31M Hold
155,044
– – 0.01% 685
2024
Q3 		$4.45M Sell
155,044
-82,450
-35% -$2.15M 0.01% 661
2024
Q2 		$5.57M Buy
237,494
+4,950
+2% +$106K 0.01% 594
2024
Q1 		$5.87M Sell
232,544
-720
-0.3% -$17.3K 0.01% 578
2023
Q4 		$5.45M Buy
233,264
+650
+0.3% +$12.8K 0.01% 607
2023
Q3 		$11.8M Buy
232,614
+55,000
+31% +$2.56M 0.03% 347
2023
Q2 		$8.29M Buy
177,614
+2,050
+1% +$93.9K 0.02% 470
2023
Q1 		$6.72M Buy
175,564
+12,300
+8% +$548K 0.01% 493
2022
Q4 		$8.95M Sell
163,264
-6,770
-4% -$290K 0.02% 439
2022
Q3 		$5.79M Buy
170,034
+98,543
+138% +$1.51M 0.01% 490
2022
Q2 		$676K Buy
71,491
+46,206
+183% +$482K ﹤0.01% 1317
2022
Q1 		$359K Hold
25,285
– – ﹤0.01% 1688
2021
Q4 		$535K Hold
25,285
– – ﹤0.01% 1603
2021
Q3 		$565K Hold
25,285
– – ﹤0.01% 1597
2021
Q2 		$628K Hold
25,285
– – ﹤0.01% 1548
2021
Q1 		$733K Hold
25,285
– – ﹤0.01% 1518
2020
Q4 		$652K Buy
25,285
+5,964
+31% +$166K ﹤0.01% 1543
2020
Q3 		$595K Sell
19,321
-7,881
-29% -$275K ﹤0.01% 1485
2020
Q2 		$678K Buy
27,202
+11,933
+78% +$273K ﹤0.01% 1400
2020
Q1 		$324K Sell
15,269
-8,554
-36% -$183K ﹤0.01% 1472
2019
Q4 		$529K Buy
+23,823
New +$493K ﹤0.01% 1499

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ensign Peak Advisors's AKRO Position: Q4 2025 in Review

Ensign Peak Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 207,692 shares — an estimated $9.86M sold.

Ensign Peak Advisors first reported a position in AKRO in Q4 2019 and held it in 24 quarters. The position peaked at $11.8M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Ensign Peak Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 207,692 Akero Therapeutics shares in Q4 2025, an estimated $9.86M.
  • Ensign Peak Advisors first reported a position in Akero Therapeutics in Q4 2019 and held it in 24 quarters.
  • Ensign Peak Advisors's Akero Therapeutics position peaked at $11.8M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Ensign Peak Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.